We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+24.54%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$278M
AUM Growth
+$61.2M
Cap. Flow
+$17.6M
Cap. Flow %
6.32%
Top 10 Hldgs %
51.21%
Holding
67
New
9
Increased
19
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.7M
2
MRK icon
Merck
MRK
+$7.14M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.27M
4
HALO icon
Halozyme
HALO
+$4.42M
5
BIIB icon
Biogen
BIIB
+$3.88M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$17M
2
INSM icon
Insmed
INSM
+$6.57M
3
PTCT icon
PTC Therapeutics
PTCT
+$5.18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.7M
5
INCY icon
Incyte
INCY
+$2.78M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVCR icon
26
NovoCure
NVCR
$2.09B
$2.99M 1.08%
+35,500
New +$2.87M
SAGE
27
DELISTED
Sage Therapeutics
SAGE
$2.98M 1.07%
41,400
+25,400
+159% +$3.12M
SGMO
28
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.53M 0.91%
303,000
-47,000
-13% -$432K
ONC
29
BeOne Medicines Ltd
ONC
$42.1B
$2.32M 0.84%
+14,000
New +$2.33M
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$2.22M 0.8%
42,700
+28,300
+197% +$1.3M
MYOK
31
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.19M 0.79%
30,000
– –
TPTX
32
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.18M 0.79%
+35,000
New +$1.67M
ASND icon
33
Ascendis Pharma A/S
ASND
$16.4B
$1.92M 0.69%
13,800
– –
GBT
34
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.84M 0.66%
23,100
+4,600
+25% +$273K
EXEL icon
35
Exelixis
EXEL
$13.7B
$1.82M 0.66%
103,534
– –
ESPR
36
DELISTED
Esperion Therapeutics
ESPR
$1.79M 0.64%
+30,000
New +$1.35M
AGIO icon
37
Agios Pharmaceuticals
AGIO
$2.05B
$1.74M 0.63%
36,500
– –
MNTA
38
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.57M 0.57%
80,000
– –
STRO icon
39
Sutro Biopharma
STRO
$353M
$1.53M 0.55%
13,933
– –
BLUE
40
DELISTED
bluebird bio
BLUE
$1.49M 0.54%
1,312
– –
GMED icon
41
Globus Medical
GMED
$11.1B
$1.43M 0.51%
24,200
– –
TCDA
42
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.39M 0.5%
37,000
– –
BPMC
43
DELISTED
Blueprint Medicines
BPMC
$1.36M 0.49%
17,000
– –
CRSP icon
44
CRISPR Therapeutics
CRSP
$5.74B
$1.34M 0.48%
+22,000
New +$1.2M
TPST icon
45
Tempest Therapeutics
TPST
$17.9M
$1.19M 0.43%
912
– –
GWPH
46
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.07M 0.38%
10,200
-9,600
-48% -$1.08M
DCPH
47
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.06M 0.38%
17,000
– –
EXAS
48
DELISTED
Exact Sciences
EXAS
$989K 0.36%
10,700
– –
QURE icon
49
uniQure
QURE
$3.44B
$967K 0.35%
13,500
-14,000
-51% -$769K
FOLD
50
DELISTED
Amicus Therapeutics
FOLD
$920K 0.33%
94,600
+36,000
+61% +$330K
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2019 Portfolio in Review

As of Q4 2019, International Biotechnology Trust held 67 positions worth $278M, up 28% from $216M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

International Biotechnology Trust deployed $17.6M of net new capital in Q4 2019, opening 9 new positions and adding to 19 existing holdings. Its largest new stake was Merck: 86,984 shares worth $7.55M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $6.57M trimmed.

  • International Biotechnology Trust's largest Q4 2019 buy was Merck: 86,984 shares worth $7.55M.
  • International Biotechnology Trust added most to Acadia Pharmaceuticals in Q4 2019, an estimated $11.7M increase.
  • International Biotechnology Trust's biggest Q4 2019 reduction was Insmed, cutting an estimated $6.57M.
  • International Biotechnology Trust fully exited Celgene Corp in Q4 2019, selling an estimated $17M.
  • International Biotechnology Trust's ten largest holdings make up 51% of its $278M portfolio in Q4 2019.
  • International Biotechnology Trust opened 9 new positions and closed 4 in Q4 2019.
  • International Biotechnology Trust's portfolio value rose 28% quarter-over-quarter to $278M.

Based on International Biotechnology Trust's 13F filing for Q4 2019, filed 18 May 2020.